Assertio Holdings (ASRT) Non-Current Assets (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Non-Current Assets came in at $44.4 million in Q1 2026, down 39.01% year-on-year from $72.9 million in Q1 2025, and down 11.68% quarter-over-quarter from $50.3 million in Q4 2025.
Assertio Holdings (ASRT) Non-Current Assets (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Non-Current Assets across 8 years of filings, most recently posting $44.4 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $44.4 million, down 39.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $214.5 million (down 38.96% YoY), and the FY2025 annual result was $50.3 million, down 38.77% from the prior year.
- Non-Current Assets came in at $44.4 million for Q1 2026 at Assertio Holdings, down from $50.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $281.7 million in Q4 2022 to a low of $44.4 million in Q1 2026.
- The 5-year median for Non-Current Assets is $109.5 million (2024), against an average of $143.0 million.
- Across the five-year window, Non-Current Assets soared 32.32% in 2023 and plunged 62.6% in 2024, its largest moves.
- Assertio Holdings' Non-Current Assets stood at $281.7 million in 2022, then sank by 59.04% to $115.4 million in 2023, then slipped by 28.76% to $82.2 million in 2024, then sank by 38.77% to $50.3 million in 2025, then declined by 11.68% to $44.4 million in 2026.
- The last three Non-Current Assets figures came in at $44.4 million (Q1 2026), $50.3 million (Q4 2025), and $56.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.22 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.40 Bn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | 44.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.44 Mn |
| Dec 31, 2025 | 50.32 Mn |
| Sep 30, 2025 | 56.20 Mn |
| Jun 30, 2025 | 63.57 Mn |
| Mar 31, 2025 | 72.88 Mn |
| Dec 31, 2024 | 82.18 Mn |
| Sep 30, 2024 | 94.84 Mn |
| Jun 30, 2024 | 101.59 Mn |
| Mar 31, 2024 | 109.49 Mn |
| Dec 31, 2023 | 115.36 Mn |
| Sep 30, 2023 | 195.07 Mn |
| Jun 30, 2023 | 271.63 Mn |
| Mar 31, 2023 | 276.43 Mn |
| Dec 31, 2022 | 281.65 Mn |
| Sep 30, 2022 | 196.85 Mn |
| Jun 30, 2022 | 205.28 Mn |
| Mar 31, 2022 | 214.02 Mn |
| Dec 31, 2021 | 223.05 Mn |
| Sep 30, 2021 | 186.76 Mn |
| Jun 30, 2021 | 192.67 Mn |